We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evolva Concludes Licensing of EV-077 to Serodus
News

Evolva Concludes Licensing of EV-077 to Serodus

Evolva Concludes Licensing of EV-077 to Serodus
News

Evolva Concludes Licensing of EV-077 to Serodus

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evolva Concludes Licensing of EV-077 to Serodus"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evolva Holding SA and Serodus ASA (Oslo, Norway) have announced that they have signed a final licensing agreement for EV-077, Evolva’s compound targeted at diabetic nephropathy (progressive kidney disease caused by diabetes).

A binding term sheet for this transaction was signed by both parties in October of this year.

The successful divestment enables further development of EV-077 to address unmet patient needs by an experienced and committed team. It is fully in line with Evolva's shift away from pharma and towards ingredients for health, wellness and nutrition.

Serodus aims to bring EV-077 further through clinical development and at a future time point decide whether Serodus or a partner will conduct the final clinical trials.

Evolva will be entitled to licensing payments including clinical and regulatory milestones as well as a single-digit royalty on sales.

If Serodus at a later stage out-licenses the compound, Evolva will receive up to 30% of Serodus’ total licensing income.

Advertisement